Brief: BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
26/03/2025 12:36
March 26 (Reuters) - Brainstorm Cell Therapeutics Inc BCLI.O: BRAINSTORM CELL THERAPEUTICS GRANTED COMPLIANCE EXTENSION FROM NASDAQ Source text: ID:nPnbKNqMba Further company coverage: BCLI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview